Kailera Therapeutics, Inc. (NASDAQ:KLRA) Short Interest Up 96.0% in June

by · The Markets Daily

Kailera Therapeutics, Inc. (NASDAQ:KLRA – Get Free Report) was the target of a significant growth in short interest during the month of June. As of June 30th, there was short interest totaling 5,097,048 shares, a growth of 96.0% from the June 15th total of 2,599,881 shares. Approximately 3.9% of the company’s shares are short sold. Based on an average trading volume of 1,667,724 shares, the days-to-cover ratio is presently 3.1 days.

Insiders Place Their Bets

In other Kailera Therapeutics news, Director Andrew T. Kaplan purchased 8,398,438 shares of the firm’s stock in a transaction on Monday, April 20th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $134,375,008.00. Following the acquisition, the director owned 26,255,581 shares in the company, valued at approximately $420,089,296. The trade was a 47.03% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Adam Koppel acquired 1,562,500 shares of the stock in a transaction dated Monday, April 20th. The stock was acquired at an average cost of $16.00 per share, with a total value of $25,000,000.00. Following the completion of the transaction, the director owned 22,583,268 shares in the company, valued at approximately $361,332,288. This represents a 7.43% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders acquired 10,460,938 shares of company stock worth $167,375,008.

Kailera Therapeutics Trading Down 5.1%

KLRA traded down $0.98 during trading on Thursday, hitting $18.32. 378,623 shares of the company’s stock were exchanged, compared to its average volume of 803,381. The firm’s 50 day moving average price is $21.01. Kailera Therapeutics has a fifty-two week low of $17.98 and a fifty-two week high of $28.23. The company has a market cap of $2.37 billion and a PE ratio of -0.01.

Kailera Therapeutics (NASDAQ:KLRA – Get Free Report) last issued its quarterly earnings data on Tuesday, May 26th. The company reported ($3,650.00) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on KLRA. Leerink Partners started coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating and a $36.00 price target on the stock. Zacks Research upgraded shares of Kailera Therapeutics to a “hold” rating in a research report on Wednesday, May 13th. Wall Street Zen lowered Kailera Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Evercore started coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They set an “outperform” rating on the stock. Finally, TD Cowen initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $57.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Kailera Therapeutics currently has an average rating of “Buy” and a consensus target price of $42.75.

Get Our Latest Stock Report on Kailera Therapeutics

Kailera Therapeutics Company Profile

(Get Free Report)

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.

Featured Stories